

Supplemental File 1

Table S1-1. Surveillance, Epidemiology, and End Results (SEER) recodes, ICD-10 codes and Morphology codes (ICD O-3)

Cancer Outcome	SEER Recodes, ICD-10 codes &/or Morphology Codes (ICD O-3)
Oral Cavity and Pharynx	SEER recodes 20010 – 20100 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Oropharynx	ICD-10 codes: C01.9, C02.4, C05.1-2, C09.0-1, C09.8-9, C10.0-4, C10.8-9
Hypopharynx	ICD-10 codes: C12.9, C13.0-2, C13.8-9
Nasopharynx	ICD-10 codes: C11.0-9
Oral cavity only	ICD-10 codes: C00.0–9; C02.0–3; C03.0–1; C03.9, C04.0–1; C04.8–9; C05.0; C06.0–2; C06.8–9
Overlapping/other	ICD-10 codes: C02.8-9, C05.8-9, C07.9, C08.0-1, C14.0, C14.2, C14.8
Squamous cell oral cancer	SEER recodes 20010 – 20100 and ICD O-3 codes: 8070 – 8074, 8076, 8083, 8560
Esophagus	SEER recode 21010 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Adenocarcinoma	ICD O-3 codes: 8140, 8143–44, 8255, 8260, 8480–81, 8560
Squamous cell	8070–72, 8083–8084, 8560
Stomach	SEER recode: 21020 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Liver and bile duct	SEER recodes: 21071 and 21072 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Gallbladder	SEER recode: 21080 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Pancreas	SEER recode: 21100 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Larynx	SEER recode: 22020 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Lung and Bronchus	SEER recode: 22030 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Large cell	ICD O-3 codes: 8012-8014, 8021, 8034, 8082
Small cell	ICD O-3 codes: 8002-8005, 8041-8045
Non-small cell	ICD O-3 code: 8046
Squamous cell	ICD O-3 codes: 8052, 8070-8076, 8078, 8083-8084, 8094, 8120, 8123, 8560
Adenocarcinoma	ICD O-3 codes: 8050, 8140-8141, 8144, 8201, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8470, 8480-8481, 8490, 8507, 8550, 8560, 8570, 8572, 8574, 8576
Colon and Rectum	SEER recodes: 21041 – 21052 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Adenocarcinoma	ICD O-3 codes: 8140, 8210-8211, 8220-8221, 8245, 8255, 8261-8263, 8480-8481, 8560, 8574
Colon	SEER recodes: 21041 - 21049
Rectum only	SEER recode: 21052
Rectosigmoid Junction	SEER recode: 21051
Small Intestine	SEER recode: 21030 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Anus	SEER recode: 21060 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)

Cancer Outcome	SEER Recodes, ICD-10 codes &/or Morphology Codes (ICD O-3)
Urinary Bladder (malignant and in-situ)	SEER recode: 29010 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Papillary Transitional Cell Carcinoma	ICD O-3 codes: 8050, 8121, 8130-8131
Non-papillary Transitional Cell Carcinoma	ICD O-3 codes: 8120, 8122
Urothelial	ICD O-3 codes: 8050, 8120-8122, 8130-8131
Bladder – malignant	SEER recode: 29010, behavior code = 3
Bladder – in-situ	SEER recode: 29010, behavior code = 2
Kidney and Renal Pelvis	SEER recode: 29020 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Renal cell and clear cell carcinoma	ICD O-3 codes: 8310, 8312
Renal cell carcinoma, NOS	ICD O-3 code: 8312
Clear cell only	ICD O-3 code: 8310
Papillary	ICD O-3 code: 8260
Brain and other CNS	SEER recodes: 31010 and 31040 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Gliomas	ICD O-3 codes: 9380–9384, 9391–9460
Soft Tissue Sarcoma	SEER recode: 24000 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Melanoma	SEER recode: 25010 (ICD-10 codes: C44.0-44.9; ICD O-3 codes: 8720-8790)
Thyroid	SEER recode: 32010 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Mesothelioma	SEER recode: 36010, ICD O-3 codes: 9050-9055
Leukemias	SEER recodes: 35011 - 35043
Lymphoid cancers	SEER recodes: 33011-33012, 33041-33042, 34000, 35011-35013
Hodgkin lymphoma	SEER recodes: 33011-33012
Non-Hodgkin lymphoma	SEER recodes: 33041-33042
Mantle Cell	ICD O-3 code: 9673
Follicular	ICD O-3 codes: 9690-9691, 9695, 9698
Diffuse Large B-cell	ICD O-3 code: 9680
Burkitt	ICD O-3 codes: 9687, 9826
Marginal Zone B-cell	ICD O-3 code: 9699
Multiple Myeloma	SEER recode: 34000
Acute lymphocytic leukemia	SEER recode: 35011
Chronic lymphocytic leukemia	SEER recode: 35012
Myeloid cancers	SEER recodes: 35021-35023, 35031, and ICD O-3 codes: 9960, 9975, 9980, 9982-9986, 9989
Acute myeloid leukemia [‡]	SEER recodes: 35021, 35031

Cancer Outcome	SEER Recodes, ICD-10 codes &/or Morphology Codes (ICD O-3)
Chronic myeloid leukemia	SEER recode: 35022
Myelodysplastic and myeloproliferative syndromes	ICD O-3 codes: 9960, 9975, 9980, 9982-9986, 9989
Polycythemia Vera	ICD O-3 code: 9950
Female Breast	SEER recode: 26000 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Ductal carcinoma	ICD O-3 code: 8500
Lobular carcinoma	ICD O-3 code: 8520
Duct-lobular carcinoma	ICD O-3 code: 8522
Male Breast	SEER recode: 26000 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Cervix	SEER recode: 27010 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Uterus	SEER recode: 27020, 27030 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Ovary	SEER recode: 27040(excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Prostate	SEER recode: 28010 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Testis	SEER recode: 28020 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)
Penis	SEER recode: 28030 (excluding ICD O-3 codes: 9050-9055, 9140, 9590-9992)

Abbreviations: ICD – International Classification of Diseases, ICD O-3 – International Classification of Diseases for Oncology, third edition, NOS – Not otherwise specified, CNS – Central nervous system

‡ includes acute monocytic leukemia.

Table S1-2. Demographic information for the Marines/Navy personnel full cohort at risk during the follow-up period

Factor	Camp Lejeune N=208,063 (47.9%)	Camp Pendleton (ref) N=225,999 (52.1%)	Total N=434,062
Male	199,285 (95.8%)	219,217 (97.0%)	418,502 (96.4%)
Female	8,778 (4.2%)	6,782 (3.0%)	15,560 (3.6%)
White	154,093 (74.1%)	179,869 (79.6%)	333,962 (76.9%)
African American	49,258 (23.7%)	35,922 (15.9%)	85,180 (19.6%)
Other or unknown race	4,712 (2.3%)	10,208 (4.5%)	14,920 (3.4%)
Rank E1 – E4	151,647 (72.9%)	158,747 (70.2%)	310,394 (71.5%)
Rank E5 – E9	44,796 (21.5%)	51,346 (22.7%)	96,142 (22.1%)
WO or CO	11,620 (5.6%)	15,906 (7.0%)	27,526 (6.3%)
Not a high school graduate	33,717 (16.2%)	40,037 (17.7%)	73,754 (17.0%)
High school graduate	163,855 (78.8%)	171,200 (75.8%)	335,055 (77.2%)
College graduate	10,491 (5.0%)	14,762 (6.5%)	25,253 (5.8%)
Age at start of follow-up (1/1/1996)			
Mean (years)	37.3	37.8	37.6
Median (years)	37	37	37
Age at end of follow-up (12/31/2017 or date of death)			
Mean	58.3	58.8	58.5
Median	58	58	58
Age ≥60 years	85,395 (40.5%)	94,385 (42.1%)	179,780 (41.4%)
Age >69 years	8,739 (4.2%)	11,964 (5.3%)	20,703 (4.8%)
Died during 1/2/1996 – 12/31/2017	24,689 (11.9%)	27,451 (12.1%)	52,140 (12.0%)
Length of follow-up (years)			
Mean (years)	20.1	20.1	20.1
Median (years)	21	21	21
Total person-years of follow-up	4,176,744	4,533,157	8,709,901

Cancers	Camp Lejeune	Camp Pendleton	Total
Total number of malignancies (including bladder cancer in situ)	23,131	23,581	46,712
Total number of individuals with any malignancy or bladder cancer in situ	21,013	21,500	42,513

Abbreviations: E1 – E4: private to corporal;
E5 – E9: sergeant to sergeant major;
WO: warrant officer; CO: commissioned officer

The table does not include aggregate cancer data obtained from the West Virginia and Kansas cancer registries.

Table S1-3. Standardized incidence rates and Poisson regression results: full cohort of Marines/Navy personnel

CANCER	Camp Lejeune			Camp Pendleton			RR (CL vs CP)*
	N	SIR	95% CI	N	SIR	95% CI	
Oral Cavity and Pharynx	1,234	1.14	(1.08, 1.21)	1,372	1.13	(1.07, 1.19)	1.04 (0.98, 1.11)
Esophagus	377	0.98	(0.89, 1.08)	407	0.94	(0.85, 1.03)	1.08 (0.99, 1.18)
Stomach	344	0.86	(0.77, 0.95)	391	0.88	(0.79, 0.97)	0.98 (0.85, 1.12)
Liver and bile duct	631	1.01	(0.93, 1.09)	763	1.11	(1.03, 1.19)	0.94 (0.86, 1.02)
Pancreas	547	0.96	(0.88, 1.04)	581	0.91	(0.84, 0.99)	1.05 (0.95, 1.18)
Gallbladder	18	0.66	(0.35, 0.96)	24	0.78	(0.47, 1.10)	0.83 (0.61, 1.13)
Larynx	401	1.08	(0.98, 1.19)	361	0.89	(0.80, 0.99)	1.26 (1.15, 1.39)
Lung and Bronchus	3,030	1.04	(1.00, 1.08)	3,084	0.95	(0.91, 0.98)	1.13 (1.07, 1.20)
Melanoma	1,580	1.45	(1.38, 1.52)	1,909	1.44	(1.37, 1.50)	1.01 (0.96, 1.07)
Urinary Bladder	982	0.98	(0.92, 1.05)	1,109	0.92	(0.87, 0.98)	1.06 (0.96, 1.16)
Kidney and Renal Pelvis	1,224	1.04	(0.98, 1.10)	1,303	1.00	(0.94, 1.05)	1.05 (0.96, 1.14)
Brain and CNS	631	1.71	(1.57, 1.84)	662	1.56	(1.44, 1.68)	1.09 (0.99, 1.19)
Thyroid	372	0.87	(0.78, 0.95)	377	0.78	(0.71, 0.86)	1.10 (0.97, 1.24)
NHL	922	0.88	(0.83, 0.94)	1,010	0.86	(0.80, 0.91)	1.03 (0.96, 1.12)
Multiple Myeloma	318	0.89	(0.79, 0.98)	339	0.89	(0.80, 0.99)	0.98 (0.86, 1.11)
Leukemias	554	0.90	(0.82, 0.97)	604	0.85	(0.78, 0.92)	1.05 (0.94, 1.17)
Colon and rectum	1,924	0.82	(0.78, 0.85)	2,146	0.82	(0.78, 0.85)	0.99 (0.92, 1.07)
Colon	1,209	0.81	(0.76, 0.85)	1,373	0.83	(0.79, 0.87)	0.97 (0.88, 1.06)
Rectum	733	0.86	(0.79, 0.92)	803	0.83	(0.77, 0.89)	1.02 (0.94, 1.11)
Anus	105	0.98	(0.79, 1.17)	138	1.23	(1.02, 1.43)	0.82 (0.70, 0.96)
Soft Tissue Sarcoma	169	0.95	(0.80, 1.09)	167	0.85	(0.72, 0.98)	1.12 (0.96, 1.30)
Hodgkin lymphoma	163	1.02	(0.86, 1.18)	156	0.92	(0.77, 1.06)	1.13 (0.95, 1.33)
ALL	32	0.83	(0.54, 1.11)	34	0.78	(0.52, 1.05)	1.03 (0.83, 1.29)
CLL	214	0.92	(0.80, 1.05)	270	0.99	(0.87, 1.11)	0.91 (0.79, 1.04)
AML	172	1.02	(0.87, 1.18)	146	0.76	(0.64, 0.88)	1.34 (1.14, 1.57)
CML	69	0.72	(0.55, 0.89)	88	0.82	(0.65, 0.99)	0.89 (0.73, 1.08)
Mesothelioma	28	0.71	(0.44, 0.97)	33	0.69	(0.45, 0.92)	1.00 (0.80, 1.26)
Breast Cancer - male	51	0.89	(0.64, 1.13)	40	0.64	(0.44, 0.83)	1.39 (1.05, 1.85)
Breast Cancer - female	398	1.17	(1.06, 1.29)	332	1.18	(1.05, 1.31)	0.99 (0.89, 1.10)
Prostate	5,894	0.95	(0.92, 0.97)	6,075	0.89	(0.86, 0.91)	1.04 (0.95, 1.13)
Testis	213	0.82	(0.71, 0.93)	264	0.89	(0.79, 1.00)	0.92 (0.81, 1.05)
Cervix	24	0.87	(0.52, 1.21)	20	0.95	(0.53, 1.36)	0.92 (0.67, 1.27)
Uterus	46	0.77	(0.55, 0.99)	62	1.18	(0.89, 1.47)	0.66 (0.52, 0.83)
Ovary	27	0.95	(0.59, 1.31)	26	1.07	(0.66, 1.49)	0.91 (0.64, 1.28)

Abbreviations: CP - Camp Pendleton; CL – Camp Lejeune; SIR - standardized incidence ratios; RR – risk ratio; CI – confidence interval; CNS – central nervous system; NHL – non-Hodgkin lymphoma; ALL – acute lymphocytic leukemia; CLL – chronic lymphocytic leukemia; AML – acute myeloid leukemia; CML – chronic myeloid leukemia

* Poisson regression controlling for sex, race and 5-year age groups

SIRs calculated relative to sex, race and five-year age-specific cancer incidence statistics for 1999-2017 for the United States and Puerto Rico from the CDC WONDER.

Includes cancer cases from the aggregate data provided by the West Virginia and Kansas cancer registries.

Table S1-4. Marines/Navy personnel full cohort comparison of base location at Camp Lejeune vs Camp Pendleton

Cancer Outcome	Camp Lejeune				Camp Pendleton Cases	
	Cases	Unadjusted HR	(95% CI)	Adjusted HR		(95% CI)
Malignant cancers (and bladder in-situ)	21,013	1.07	(1.05, 1.09)	1.04	(1.02, 1.06)	21,500
Oral Cavity and Pharynx	1,193	1.00	(0.93, 1.08)	1.02	(0.94, 1.11)	1,297
Oropharynx	699	1.04	(0.93, 1.15)	1.06	(0.96, 1.18)	735
Hypopharynx	59	0.91	(0.65, 1.29)	0.89	(0.63, 1.26)	71
Nasopharynx	39	0.90	(0.59, 1.38)	0.94	(0.61, 1.45)	47
Oral cavity only	222	0.96	(0.80, 1.15)	0.98	(0.82, 1.18)	251
Overlapping/other	83	1.14	(0.84, 1.55)	1.16	(0.85, 1.58)	79
Squamous cell oral cancer	1,061	1.02	(0.94, 1.11)	1.04	(0.96, 1.13)	1,187
Esophagus	381	1.07	(0.93, 1.23)	1.07	(0.93, 1.24)	390
Adenocarcinoma	235	1.00	(0.84, 1.20)	1.06	(0.89, 1.26)	256
Squamous cell	108	1.20	(0.91, 1.58)	1.09	(0.83, 1.43)	99
Stomach	349	1.00	(0.86, 1.15)	0.96	(0.83, 1.12)	383
Liver and bile duct	634	0.92	(0.83, 1.02)	0.92	(0.83, 1.02)	755
Gallbladder	18	0.90	(0.49, 1.69)	0.84	(0.45, 1.57)	22
Pancreas	558	1.07	(0.95, 1.20)	1.04	(0.93, 1.17)	571
Larynx	375	1.24	(1.07, 1.43)	1.21	(1.04, 1.40)	332
Lung and Bronchus	3,083	1.15	(1.10, 1.21)	1.13	(1.07, 1.19)	2,939
Large cell	89	1.17	(0.87, 1.58)	1.14	(0.85, 1.55)	83
Small cell	412	1.14	(1.00, 1.31)	1.14	(1.00, 1.31)	396
Non-small cell	338	1.21	(1.04, 1.42)	1.18	(1.01, 1.38)	305
Squamous cell	768	1.26	(1.14, 1.40)	1.23	(1.11, 1.37)	672
Adenocarcinoma	1,214	1.12	(1.03, 1.21)	1.08	(1.00, 1.17)	1,195
Colon and Rectum	1,799	1.01	(0.95, 1.08)	0.98	(0.92, 1.05)	1,948
Adenocarcinoma	1,562	0.99	(0.93, 1.06)	0.97	(0.91, 1.04)	1,719
Colon	1,119	0.99	(0.91, 1.07)	0.95	(0.87, 1.03)	1,240
Rectum only	571	1.07	(0.95, 1.20)	1.05	(0.93, 1.18)	584

Cancer Outcome	Camp Lejeune					Camp Pendleton Cases
	Cases	Unadjusted HR	(95% CI)	Adjusted HR	(95% CI)	
Rectosigmoid Junction	143	0.94	(0.75, 1.17)	0.95	(0.76, 1.19)	166
Small Intestine	110	0.83	(0.65, 1.07)	0.79	(0.62, 1.02)	144
Anus	83	0.88	(0.66, 1.18)	0.85	(0.64, 1.14)	102
Urinary Bladder (malignant and in-situ)	1,001	1.03	(0.94, 1.12)	1.05	(0.96, 1.14)	1,072
Papillary Transitional Cell Carcinoma	712	1.06	(0.96, 1.18)	1.09	(0.98, 1.21)	736
Non-papillary Transitional Cell Carcinoma	257	0.99	(0.83, 1.17)	0.99	(0.83, 1.17)	287
Urothelial	969	1.04	(0.95, 1.14)	1.06	(0.97, 1.16)	1,023
Bladder – malignant	497	0.98	(0.87, 1.10)	0.99	(0.87, 1.11)	559
Bladder – in-situ	524	1.08	(0.95, 1.21)	1.11	(0.98, 1.25)	535
Kidney and Renal Pelvis	1,211	1.06	(0.98, 1.14)	1.04	(0.96, 1.12)	1,251
Renal cell and clear cell carcinoma	879	0.99	(0.90, 1.09)	1.00	(0.91, 1.09)	967
Renal cell carcinoma, NOS	448	1.12	(0.98, 1.28)	1.09	(0.96, 1.25)	434
Clear cell only	437	0.88	(0.78, 1.00)	0.92	(0.81, 1.04)	540
Papillary	162	1.30	(1.03, 1.63)	1.11	(0.89, 1.40)	137
Brain and other CNS	351	1.03	(0.89, 1.19)	1.05	(0.91, 1.22)	367
Gliomas	317	1.06	(0.90, 1.23)	1.08	(0.93, 1.26)	324
Soft Tissue Sarcoma	171	1.15	(0.93, 1.43)	1.14	(0.92, 1.41)	161
Melanoma	1,048	0.97	(0.90, 1.06)	1.05	(0.96, 1.14)	1,174
Thyroid	371	1.07	(0.93, 1.24)	1.08	(0.93, 1.25)	374
Mesothelioma	28	0.94	(0.57, 1.55)	0.93	(0.56, 1.53)	33
Leukemias	566	1.05	(0.93, 1.18)	1.05	(0.93, 1.18)	589
Lymphoid cancers	1,686	1.04	(0.97, 1.11)	1.02	(0.96, 1.09)	1,765
Hodgkin lymphoma	164	1.13	(0.91, 1.41)	1.11	(0.89, 1.39)	156
Non-Hodgkin lymphoma	937	1.05	(0.96, 1.15)	1.05	(0.96, 1.15)	971
Mantle Cell	51	1.21	(0.81, 1.80)	1.25	(0.84, 1.87)	46
Follicular	206	1.07	(0.88, 1.30)	1.12	(0.92, 1.36)	208
Diffuse Large B-cell	291	1.00	(0.85, 1.17)	1.01	(0.86, 1.19)	315
Burkitt	21	1.12	(0.61, 2.07)	1.26	(0.68, 2.34)	20
Marginal Zone B-cell	72	1.33	(0.95, 1.88)	1.33	(0.94, 1.89)	59
Multiple Myeloma	325	1.08	(0.93, 1.26)	0.99	(0.84, 1.15)	329

Cancer Outcome	Camp Lejeune				Camp Pendleton Cases	
	Cases	Unadjusted HR	(95% CI)	Adjusted HR		(95% CI)
Acute lymphocytic leukemia	33	1.03	(0.64, 1.67)	1.03	(0.64, 1.67)	34
Chronic lymphocytic leukemia	219	0.90	(0.75, 1.07)	0.90	(0.75, 1.07)	267
Myeloid cancers (including polycythemia vera, myelodysplastic and myeloproliferative syndromes)	434	1.17	(1.02, 1.34)	1.17	(1.02, 1.34)	434
Myeloid cancers (including myelodysplastic and myeloproliferative syndromes)	352	1.17	(1.01, 1.35)	1.16	(1.00, 1.35)	354
Acute myeloid leukemia [¥]	174	1.33	(1.07, 1.66)	1.34	(1.07, 1.67)	142
Chronic myeloid leukemia	70	0.87	(0.64, 1.20)	0.87	(0.64, 1.20)	87
Myelodysplastic and myeloproliferative syndromes	126	1.24	(0.97, 1.59)	1.23	(0.96, 1.58)	124
Polycythemia Vera	84	1.17	(0.86, 1.60)	1.23	(0.90, 1.68)	78
Female Breast	316	1.07	(0.91, 1.26)	1.07	(0.90, 1.26)	256
Ductal carcinoma	237	1.12	(0.92, 1.36)	1.11	(0.91, 1.35)	182
Lobular carcinoma	23	0.68	(0.40, 1.18)	0.75	(0.43, 1.30)	30
Duct-lobular carcinoma	17	1.28	(0.60, 2.73)	1.39	(0.64, 2.99)	11
Male Breast	42	1.28	(0.82, 2.00)	1.24	(0.79, 1.93)	36
Cervix	24	0.90	(0.50, 1.63)	0.89	(0.49, 1.62)	20
Uterus	44	0.64	(0.43, 0.95)	0.64	(0.43, 0.95)	61
Ovary	24	0.90	(0.51, 1.58)	0.90	(0.51, 1.60)	24
Prostate	6,055	1.14	(1.10, 1.18)	1.05	(1.01, 1.09)	5,887
Testis	212	0.87	(0.73, 1.04)	0.91	(0.76, 1.09)	263
Penis	32	1.46	(0.86, 2.48)	1.49	(0.87, 2.53)	24

Abbreviations: HR – hazard ratio; CI – confidence interval; NOS-;CNS-

[¥] includes acute monocytic leukemia

HRs adjusted for sex, race, rank and education level; age was the time variable

Supplemental File 2

Figure 1: Smoking prevalence required to fully explain the HR of 1.08 in the Marines/Navy personnel sub-group analysis of COPD mortality as an underlying cause and base location, assuming RRs for smoking and COPD between 3.0 and 5.5.

Multidimensional HR CL-COPD Relationship Adjusted for smoking													
p(smoking+ CL+)*	P(smoking+ CL-)#	RR(smoking-COPD):	RR										
			3	3.25	3.5	3.75	4	4.25	4.5	4.75	5	5.25	5.5
0.45	0.44		1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07
0.47	0.45		1.06	1.06	1.06	1.06	1.06	1.05	1.05	1.05	1.05	1.05	1.05
0.49	0.46		1.05	1.05	1.05	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04
0.51	0.47		1.04	1.04	1.04	1.03	1.03	1.03	1.03	1.03	1.03	1.02	1.02
0.53	0.48		1.03	1.03	1.02	1.02	1.02	1.02	1.02	1.01	1.01	1.01	1.01
0.55	0.49		1.02	1.02	1.01	1.01	1.01	1.01	1.00	1.00	1.00	1.00	1.00
0.57	0.50		1.01	1.01	1.00	1.00	1.00	1.00	0.99	0.99	0.99	0.99	0.99
0.59	0.51		1.00	1.00	1.00	0.99	0.99	0.99	0.98	0.98	0.98	0.98	0.98
0.61	0.52		0.99	0.99	0.99	0.98	0.98	0.98	0.97	0.97	0.97	0.97	0.97
0.63	0.53		0.99	0.98	0.98	0.97	0.97	0.97	0.96	0.96	0.96	0.96	0.96
0.65	0.54		0.98	0.97	0.97	0.97	0.96	0.96	0.96	0.95	0.95	0.95	0.95

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

For smoking to fully account for the COPD HR of 1.08, the smoking prevalence difference between Camp Lejeune and Camp Pendleton would be 6%, corresponding to 55% prevalence at Camp Lejeune and 49% prevalence at Camp Pendleton (i.e., the prevalence difference resulting in the HR=1.00).

HR – hazard ratio
 RR – risk ratio
 COPD – Chronic obstructive pulmonary disease

Figure 2: Impact of adjusting for a smoking prevalence difference of 6% between CL and CP on the HR of 1.16 for lung cancer in the Marines/Navy personnel subgroup analysis of base location, and the smoking prevalence difference necessary to fully explain the HR of 1.16 for lung cancer. The RRs for smoking and lung cancer are assumed to be between 7.0 and 12.0.

Multidimensional HR CL-lung cancer Relationship Adjusted for smoking													
p(smoking+ CL+)*	p(smoking+ CL-)#	RR(smoking-lung cancer):	RR(smoking-lung cancer):										
			7	7.5	8	8.5	9	9.5	10	10.5	11	11.5	12
0.45	0.42		1.11	1.11	1.11	1.10	1.10	1.10	1.10	1.10	1.10	1.10	1.10
0.47	0.43		1.09	1.09	1.09	1.09	1.09	1.09	1.09	1.08	1.08	1.08	1.08
0.49	0.44		1.08	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.07	1.06
0.51	0.45		1.06	1.06	1.06	1.06	1.05	1.05	1.05	1.05	1.05	1.05	1.05
0.53	0.46		1.05	1.05	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.03
0.55	0.47		1.03	1.03	1.03	1.03	1.03	1.03	1.03	1.02	1.02	1.02	1.02
0.57	0.48		1.02	1.02	1.02	1.02	1.01	1.01	1.01	1.01	1.01	1.01	1.01
0.59	0.49		1.01	1.01	1.01	1.00	1.00	1.00	1.00	1.00	1.00	0.99	0.99
0.61	0.50		1.00	1.00	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.98	0.98
0.63	0.51		0.99	0.99	0.98	0.98	0.98	0.98	0.98	0.98	0.97	0.97	0.97
0.65	0.52		0.98	0.98	0.97	0.97	0.97	0.97	0.97	0.97	0.96	0.96	0.96

* Prevalence of smoking at Camp Lejeune

Prevalence of smoking at Camp Pendleton

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

First highlighting: reduction in the HR for lung cancer by adjusting for a 6% difference in smoking prevalence between Camp Lejeune and Camp Pendleton. The HR of 1.16 for lung cancer would decrease to 1.05.

Second highlighting: Prevalence difference in smoking between the two bases to fully explain the lung cancer HR of 1.16 (i.e., the prevalence difference resulting in the HR=1.00). The prevalence difference would need to be at least 10%.

* Prevalence of smoking at Camp Lejeune
Prevalence of smoking at Camp Pendleton

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

The first table indicates the reduction in the HR for laryngeal cancer by adjusting for a 6% difference in smoking prevalence between Camp Lejeune and Camp Pendleton (highlighted). The HR of 1.21 for laryngeal cancer would decrease to between 1.10 and 1.11.

The second table indicates the prevalence difference required to fully explain the laryngeal cancer HR of 1.21, (i.e., the prevalence difference resulting in the HR=1.00, highlighted). The prevalence difference would need to be at least 12%.

Figure 4: Impact of adjusting the esophageal cancer HR of 1.27 by smoking assuming a 6% smoking prevalence difference between the Camp Lejeune and Camp Pendleton subgroup of Marines/Navy personnel. The RRs for smoking and esophageal cancer are assumed to be between 1.3 and 4.5.

Multidimensional HR CL-esophagus Relationship Adjusted for smoking													
p(smoking+ CL+)*	P(smoking+ CL-)#	RR(smoking-esophagus):	RR(smoking-esophagus):										
			1.3	1.5	1.8	2	2.3	2.5	2.8	3	3.5	4	4.5
0.45	0.44		1.27	1.27	1.26	1.26	1.26	1.26	1.26	1.26	1.26	1.25	1.25
0.47	0.45		1.26	1.26	1.26	1.25	1.25	1.25	1.25	1.24	1.24	1.24	1.24
0.49	0.46		1.26	1.26	1.25	1.25	1.24	1.24	1.23	1.23	1.23	1.22	1.22
0.51	0.47		1.26	1.25	1.24	1.24	1.23	1.23	1.22	1.22	1.22	1.21	1.21
0.53	0.48		1.25	1.25	1.24	1.23	1.22	1.22	1.21	1.21	1.20	1.20	1.19
0.55	0.49		1.25	1.24	1.23	1.22	1.21	1.21	1.20	1.20	1.19	1.18	1.18
0.57	0.50		1.25	1.24	1.22	1.21	1.20	1.20	1.19	1.19	1.18	1.17	1.17
0.59	0.51		1.25	1.23	1.22	1.21	1.20	1.19	1.18	1.18	1.17	1.16	1.15
0.61	0.52		1.24	1.23	1.21	1.20	1.19	1.18	1.17	1.17	1.16	1.15	1.14
0.63	0.53		1.24	1.22	1.20	1.19	1.18	1.17	1.16	1.16	1.15	1.14	1.13
0.65	0.54		1.24	1.22	1.20	1.19	1.17	1.16	1.16	1.15	1.14	1.13	1.12

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

The reduction in the HR for esophageal cancer by adjusting for a 6% difference in smoking prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.27 for esophageal cancer would decrease to between 1.18 and 1.25.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 5. Alcohol use prevalence required to fully explain the HR of 0.93 in the Marines/Navy personnel subgroup analysis of chronic liver disease mortality as an underlying cause and base location. The RRs for alcohol consumption and chronic liver disease mortality are assumed to be between 2.5 and 10.0.

Multidimensional HR CL-chronic liver disease mortality Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)*	p(alcohol use+ CL-)#	RR(alcohol use-chronic liver disease mortality):	RR values for alcohol consumption (2.5 to 10.0)										
			2.5	3	3.5	4	5	6	6.5	7	8	9	10
0.67	0.69		0.94	0.94	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
0.67	0.70		0.95	0.95	0.95	0.96	0.96	0.96	0.96	0.96	0.96	0.96	0.96
0.67	0.71		0.96	0.96	0.96	0.97	0.97	0.97	0.97	0.97	0.97	0.97	0.98
0.67	0.72		0.96	0.97	0.97	0.97	0.98	0.98	0.98	0.98	0.98	0.99	0.99
0.67	0.73		0.97	0.98	0.98	0.98	0.99	0.99	0.99	0.99	0.99	1.00	1.00
0.67	0.74		0.98	0.98	0.99	0.99	1.00	1.00	1.00	1.01	1.01	1.01	1.01
0.67	0.75		0.98	0.99	1.00	1.00	1.01	1.01	1.02	1.02	1.02	1.02	1.02
0.67	0.76		0.99	1.00	1.01	1.01	1.02	1.02	1.03	1.03	1.03	1.03	1.04
0.67	0.77		1.00	1.01	1.02	1.02	1.03	1.03	1.04	1.04	1.04	1.05	1.05
0.67	0.78		1.00	1.02	1.02	1.03	1.04	1.05	1.05	1.05	1.05	1.06	1.06
0.67	0.79		1.01	1.02	1.03	1.04	1.05	1.06	1.06	1.06	1.07	1.07	1.07

To fully explain the HR of 0.93 for chronic liver disease mortality and base location, the prevalence difference between CL and CP would range between 6% and 10% (highlighted).

Alcohol use and liver cirrhosis mortality RRs: 2.65 for 25 g/day, 6.83 for 50 g/day, and 16.38 for 100 g/day. Llamosas-Falcon L, Probst C, Buckler C, Jiang H et al. How does alcohol use impact morbidity and mortality of liver cirrhosis? A systematic review and dose-response meta-analysis. Hepatology International 08 September 2023 online ahead of print.

* Prevalence of alcohol use at Camp Lejeune
 # Prevalence of alcohol use at Camp Pendleton

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 6. Alcohol use prevalence required to fully explain the hazard ratio of 0.88 in the Marines/Navy personnel subgroup analysis of chronic liver disease mortality as a contributing cause and base location.

Multidimensional HR CL-chronic liver disease mortality Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)*	P(alcohol use+ CL-)#	RR(alcohol use-chronic liver disease mortality):											
			2.5	3	3.5	4	5	6	6.5	7	8	9	10
0.67	0.74		0.92	0.93	0.94	0.94	0.95	0.95	0.95	0.95	0.95	0.96	0.96
0.67	0.75		0.93	0.94	0.94	0.95	0.95	0.96	0.96	0.96	0.96	0.97	0.97
0.67	0.76		0.94	0.95	0.95	0.96	0.96	0.97	0.97	0.97	0.98	0.98	0.98
0.67	0.77		0.94	0.95	0.96	0.97	0.97	0.98	0.98	0.98	0.99	0.99	0.99
0.67	0.78		0.95	0.96	0.97	0.97	0.98	0.99	0.99	0.99	1.00	1.00	1.00
0.67	0.79		0.96	0.97	0.98	0.98	0.99	1.00	1.00	1.00	1.01	1.01	1.01
0.67	0.80		0.96	0.98	0.99	0.99	1.00	1.01	1.01	1.01	1.02	1.02	1.02
0.67	0.81		0.97	0.98	0.99	1.00	1.01	1.02	1.02	1.03	1.03	1.03	1.04
0.67	0.82		0.98	0.99	1.00	1.01	1.02	1.03	1.03	1.04	1.04	1.04	1.05
0.67	0.83		0.98	1.00	1.01	1.02	1.03	1.04	1.04	1.05	1.05	1.06	1.06
0.67	0.84		0.99	1.01	1.02	1.03	1.04	1.05	1.05	1.06	1.06	1.07	1.07

To fully explain the HR of 0.88 for chronic liver disease mortality and base location, the prevalence difference between CL and CP would range between 11% and 16% (highlighted).

* Prevalence of alcohol use at Camp Lejeune
 # Prevalence of alcohol use at Camp Pendleton

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 7. Impact of adjusting for alcohol use prevalence difference of 10% between CL and CP on the HR of 1.47 for squamous cell esophageal cancer in the Marines/Navy personnel subgroup analysis of base location. The RRs for alcohol use and squamous cell esophageal cancer are assumed to be between 1.25 and 5.25.

Multidimensional HR CL-sq. esophageal cancer Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)	p(alcohol use+ CL-)	RR(alcohol use-sq. esophageal cancer):	RR values for alcohol use prevalence ratios										
			1.25	1.5	1.75	2	2.5	3	3.5	4	4.5	5	5.25
0.67	0.68		1.48	1.48	1.48	1.48	1.49	1.49	1.49	1.49	1.49	1.49	1.49
0.67	0.69		1.48	1.49	1.49	1.49	1.50	1.50	1.50	1.50	1.51	1.51	1.51
0.67	0.70		1.48	1.49	1.50	1.50	1.51	1.51	1.52	1.52	1.52	1.52	1.52
0.67	0.71		1.49	1.50	1.50	1.51	1.52	1.53	1.53	1.53	1.54	1.54	1.54
0.67	0.72		1.49	1.50	1.51	1.52	1.53	1.54	1.54	1.55	1.55	1.56	1.56
0.67	0.73		1.49	1.51	1.52	1.53	1.54	1.55	1.56	1.56	1.57	1.57	1.57
0.67	0.74		1.50	1.51	1.53	1.54	1.55	1.56	1.57	1.58	1.58	1.59	1.59
0.67	0.75		1.50	1.52	1.53	1.55	1.56	1.58	1.59	1.59	1.60	1.60	1.61
0.67	0.76		1.50	1.52	1.54	1.55	1.57	1.59	1.60	1.61	1.61	1.62	1.62
0.67	0.77		1.51	1.53	1.55	1.56	1.59	1.60	1.61	1.62	1.63	1.64	1.64
0.67	0.78		1.51	1.54	1.56	1.57	1.60	1.61	1.63	1.64	1.64	1.65	1.65

The increase in the HR for squamous cell esophageal cancer by adjusting for a 10% difference in alcohol use prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.47 would increase to between 1.51 and 1.64.

RR for squamous cell esophageal cancer and moderate alcohol use (12.5g/day – 50g/day) = 2.23

RR for squamous cell esophageal cancer and heavy alcohol use (>50g/day) = 4.95

Ref: 34.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 8. Impact of adjusting for alcohol use prevalence difference of 10% between CL and CP on the HR of 1.27 for esophageal cancer in the Marines/Navy personnel subgroup analysis of base location. The RRs for alcohol use and esophageal cancer are assumed to be between 1.25 and 5.25.

Multidimensional HR CL-esophageal cancer Relationship Adjusted for alcohol													
p(alcohol+ CL+)	p(alcohol+ CL-)	RR(alcohol-esophageal cancer):											
			1.25	1.5	1.75	2	2.5	3	3.5	4	4.5	5	5.25
0.67	0.68		1.27	1.28	1.28	1.28	2.50	1.28	1.28	1.28	1.28	1.28	1.29
0.67	0.69		1.28	1.28	1.28	1.29	2.75	1.29	1.29	1.30	1.30	1.30	1.30
0.67	0.70		1.28	1.29	1.29	1.29	1.30	1.30	1.31	1.31	1.31	1.31	1.31
0.67	0.71		1.28	1.29	1.30	1.30	1.31	1.31	1.32	1.32	1.32	1.33	1.33
0.67	0.72		1.28	1.29	1.30	1.31	1.32	1.33	1.33	1.33	1.33	1.34	1.34
0.67	0.73		1.29	1.30	1.31	1.32	1.33	1.34	1.34	1.35	1.35	1.35	1.36
0.67	0.74		1.29	1.30	1.32	1.32	1.34	1.35	1.35	1.36	1.36	1.37	1.37
0.67	0.75		1.29	1.31	1.32	1.33	1.35	1.36	1.37	1.37	1.38	1.38	1.38
0.67	0.76		1.30	1.31	1.33	1.34	1.36	1.37	1.38	1.39	1.39	1.40	1.40
0.67	0.77		1.30	1.32	1.33	1.35	1.37	1.38	1.39	1.40	1.41	1.41	1.41
0.67	0.78		1.30	1.32	1.34	1.35	1.38	1.39	1.40	1.41	1.42	1.42	1.43

The increase in the HR for esophageal cancer by adjusting for a 10% difference in alcohol use prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.27 would increase to between 1.30 and 1.41.

Rrs for alcohol consumption and esophageal cancer were assumed to be similar to the Rrs for squamous cell esophageal cancer. Kunzmann AT, Coleman HG, Huang WY, Berndt SI. The association of lifetime alcohol use with mortality and cancer risk in older adults: A cohort study. PLoS Med 2018;15(6): e1002585 (Supplemental table 3).

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 9. Impact of adjusting for alcohol use prevalence difference of 10% between CL and CP on the HR of 1.21 for laryngeal cancer in the Marines/Navy personnel subgroup analysis of base location. RRs for alcohol use and laryngeal cancer are assumed to be between 1.1 and 3.0.

Multidimensional HR CL-laryngeal cancer Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)	p(alcohol use+ CL-)	RR(alcohol use-laryngeal cancer):	RRs for alcohol use and laryngeal cancer (1.1 to 3.0)										
			1.1	1.3	1.5	1.7	1.9	2.1	2.3	2.5	2.7	2.9	3
0.67	0.68		1.21	1.22	1.22	1.22	1.22	1.22	1.22	1.22	1.22	1.22	1.22
0.67	0.69		1.22	1.22	1.22	1.22	1.23	1.23	1.23	1.23	1.23	1.23	1.23
0.67	0.70		1.22	1.22	1.23	1.23	1.23	1.24	1.24	1.24	1.24	1.24	1.24
0.67	0.71		1.22	1.23	1.23	1.24	1.24	1.24	1.25	1.25	1.25	1.25	1.25
0.67	0.72		1.22	1.23	1.24	1.24	1.25	1.25	1.26	1.26	1.26	1.26	1.27
0.67	0.73		1.22	1.23	1.24	1.25	1.25	1.26	1.26	1.27	1.27	1.27	1.28
0.67	0.74		1.22	1.23	1.25	1.25	1.26	1.27	1.27	1.28	1.28	1.28	1.29
0.67	0.75		1.22	1.24	1.25	1.26	1.27	1.27	1.28	1.29	1.29	1.29	1.30
0.67	0.76		1.22	1.24	1.25	1.27	1.27	1.28	1.29	1.30	1.30	1.30	1.31
0.67	0.77		1.22	1.24	1.26	1.27	1.28	1.29	1.30	1.30	1.31	1.31	1.32
0.67	0.78		1.23	1.25	1.26	1.28	1.29	1.30	1.31	1.31	1.32	1.32	1.33

The increase in the HR for laryngeal cancer by adjusting for a 10% difference in alcohol use prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.21 would increase to between 1.22 and 1.32.

RR for laryngeal cancer and moderate alcohol use (12.5g/day – 50g/day) = 1.44

RR for laryngeal cancer and heavy alcohol use (>50g/day) = 2.65

Ref: 34.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 10: Smoking prevalence difference between Camp Lejeune and Camp Pendleton workers required to fully explain the HR of 1.05 in the analysis of COPD as a contributing cause of death.

Multidimensional HR CL-COPD Relationship Adjusted for smoking														
p(smoking+ CL+)	p(smoking+ CL-)	RR(smoking-COPD):	RR(smoking-COPD):											
			3	3.25	3.5	3.75	4	4.25	4.5	4.75	5	5.25	5.5	
0.45	0.44		1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.04
0.47	0.45		1.03	1.03	1.03	1.03	1.03	1.02	1.02	1.02	1.02	1.02	1.02	1.02
0.49	0.46		1.02	1.02	1.02	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01
0.51	0.47		1.01	1.01	1.01	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.99
0.53	0.48		1.00	1.00	1.00	0.99	0.99	0.99	0.99	0.99	0.99	0.98	0.98	0.98
0.55	0.49		0.99	0.99	0.99	0.98	0.98	0.98	0.98	0.97	0.97	0.97	0.97	0.97
0.57	0.50		0.98	0.98	0.98	0.97	0.97	0.97	0.97	0.96	0.96	0.96	0.96	0.96
0.59	0.51		0.97	0.97	0.97	0.96	0.96	0.96	0.96	0.95	0.95	0.95	0.95	0.95
0.61	0.52		0.97	0.96	0.96	0.95	0.95	0.95	0.95	0.94	0.94	0.94	0.94	0.94
0.63	0.53		0.96	0.95	0.95	0.95	0.94	0.94	0.94	0.93	0.93	0.93	0.93	0.93
0.65	0.54		0.95	0.95	0.94	0.94	0.93	0.93	0.93	0.93	0.92	0.92	0.92	0.92

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

For smoking to fully account for the COPD HR of 1.05, the smoking prevalence difference between Camp Lejeune and Camp Pendleton would be 4%, corresponding to 51% prevalence at Camp Lejeune and 47% prevalence at Camp Pendleton (i.e., the prevalence difference resulting in the HR=1.00, highlighted).

Abbreviations: HR – hazard ratio, RR – risk ratio, COPD – Chronic obstructive pulmonary disease

Figure 11: Impact of adjusting for a smoking prevalence difference of 4% between Camp Lejeune and Camp Pendleton workers on the HR of 1.15 for lung cancer, and the smoking prevalence difference necessary to fully explain the HR of 1.15 for lung cancer. The RRs for smoking and lung cancer are assumed to be between 7.0 and 12.0.

Multidimensional HR CL-lung cancer Relationship Adjusted for smoking													
p(smoking+ CL+)	p(smoking+ CL-)	RR(smoking-lung cancer):	RR										
			7	7.5	8	8.5	9	9.5	10	10.5	11	11.5	12
0.45	0.44		1.13	1.13	1.13	1.13	1.13	1.13	1.13	1.13	1.13	1.13	1.13
0.47	0.45		1.12	1.12	1.12	1.12	1.11	1.11	1.11	1.11	1.11	1.11	1.11
0.49	0.46		1.10	1.10	1.10	1.10	1.10	1.10	1.10	1.10	1.10	1.09	1.09
0.51	0.47		1.09	1.08	1.08	1.08	1.08	1.08	1.08	1.08	1.08	1.08	1.08
0.53	0.48		1.07	1.07	1.07	1.07	1.07	1.06	1.06	1.06	1.06	1.06	1.06
0.55	0.49		1.06	1.06	1.05	1.05	1.05	1.05	1.05	1.05	1.05	1.05	1.05
0.57	0.50		1.04	1.04	1.04	1.04	1.04	1.04	1.03	1.03	1.03	1.03	1.03
0.59	0.51		1.03	1.03	1.03	1.03	1.02	1.02	1.02	1.02	1.02	1.02	1.02
0.61	0.52		1.02	1.02	1.02	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01
0.63	0.53		1.01	1.01	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.99	0.99
0.65	0.54		1.00	1.00	0.99	0.99	0.99	0.99	0.99	0.99	0.98	0.98	0.98

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

First highlighting: reduction in the HR for lung cancer by adjusting for a 4% difference in smoking prevalence between Camp Lejeune and Camp Pendleton. The HR of 1.15 would decrease to between 1.08 and 1.09.

Second highlighting: Prevalence difference in smoking between the two bases to fully explain the lung cancer HR of 1.15 (i.e., the prevalence difference resulting in the HR=1.00). The prevalence difference would need to be at least 10%.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 12: Impact of adjusting for a smoking prevalence difference of 4% between Camp Lejeune and Camp Pendleton workers on the HR for laryngeal cancer of 1.18. The RRs for smoking and laryngeal cancer are assumed to be between 7.0 and 12.0.

Multidimensional HR CL-laryngeal cancer Relationship Adjusted for smoking													
p(smoking+ CL+)	p(smoking+ CL-)	RR(smoking-laryngeal cancer):	RR(smoking-laryngeal cancer):										
			7	7.5	8	8.5	9	9.5	10	10.5	11	11.5	12
0.45	0.44		1.17	1.16	1.16	1.16	1.16	1.16	1.16	1.16	1.16	1.16	1.16
0.47	0.45		1.15	1.15	1.15	1.15	1.14	1.14	1.14	1.14	1.14	1.14	1.14
0.49	0.46		1.13	1.13	1.13	1.13	1.13	1.13	1.13	1.13	1.12	1.12	1.12
0.51	0.47		1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11
0.53	0.48		1.10	1.10	1.10	1.10	1.09	1.09	1.09	1.09	1.09	1.09	1.09
0.55	0.49		1.09	1.08	1.08	1.08	1.08	1.08	1.08	1.08	1.08	1.08	1.07
0.57	0.50		1.07	1.07	1.07	1.07	1.07	1.06	1.06	1.06	1.06	1.06	1.06
0.59	0.51		1.06	1.06	1.06	1.05	1.05	1.05	1.05	1.05	1.05	1.05	1.05
0.61	0.52		1.05	1.05	1.04	1.04	1.04	1.04	1.04	1.04	1.04	1.03	1.03
0.63	0.53		1.04	1.03	1.03	1.03	1.03	1.03	1.03	1.02	1.02	1.02	1.02
0.65	0.54		1.03	1.02	1.02	1.02	1.02	1.02	1.01	1.01	1.01	1.01	1.01

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

Highlighting: reduction in the HR for laryngeal cancer by adjusting for a 4% difference in smoking prevalence between Camp Lejeune and Camp Pendleton. The HR of 1.18 would decrease to 1.11.

Note: To fully explain the laryngeal cancer HR of 1.18, the smoking prevalence difference between the two bases would be >11%.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 13: Impact of adjusting for a smoking prevalence difference of 4% between Camp Lejeune and Camp Pendleton workers on the HR for oral cancers of 1.67. The RRs for smoking and oral cancers was assumed to be between 3.5 and 7.0.

Multidimensional HR CL-oral cancers Relationship Adjusted for smoking														
p(smoking+ CL+)	p(smoking+ CL-)	RR(smoking-oral cancers):	RR values for different assumptions											
			3.5	3.75	4	4.25	4.5	4.75	5	5.5	6	6.5	7	
0.45	0.44		1.65	1.65	1.65	1.65	1.64	1.64	1.64	1.64	1.64	1.64	1.64	1.64
0.47	0.45		1.63	1.63	1.63	1.62	1.62	1.62	1.62	1.62	1.62	1.62	1.62	1.61
0.49	0.46		1.61	1.61	1.61	1.60	1.60	1.60	1.60	1.60	1.60	1.59	1.59	1.59
0.51	0.47		1.59	1.59	1.59	1.59	1.58	1.58	1.58	1.58	1.58	1.57	1.57	1.57
0.53	0.48		1.58	1.57	1.57	1.57	1.56	1.56	1.56	1.56	1.56	1.55	1.55	1.55
0.55	0.49		1.56	1.56	1.55	1.55	1.55	1.54	1.54	1.54	1.54	1.53	1.53	1.53
0.57	0.50		1.55	1.54	1.54	1.53	1.53	1.53	1.52	1.52	1.52	1.52	1.51	1.51
0.59	0.51		1.53	1.53	1.52	1.52	1.51	1.51	1.51	1.50	1.50	1.49	1.49	1.49
0.61	0.52		1.52	1.51	1.51	1.50	1.50	1.50	1.49	1.49	1.48	1.48	1.48	1.47
0.63	0.53		1.51	1.50	1.49	1.49	1.49	1.48	1.48	1.47	1.47	1.47	1.46	1.46
0.65	0.54		1.49	1.49	1.48	1.48	1.47	1.47	1.46	1.46	1.46	1.45	1.45	1.44

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

Highlighting: reduction in the HR for oral cancers by adjusting for a 4% difference in smoking prevalence between Camp Lejeune and Camp Pendleton. The HR of 1.67 would decrease to between 1.57 and 1.59.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 14: Impact of adjusting for a smoking prevalence difference of 4% between Camp Lejeune and Camp Pendleton workers on the HR for kidney cancer of 1.12.

Multidimensional HR CL-kidney cancer Relationship Adjusted for smoking													
p(smoking+ CL+)	p(smoking+ CL-)	RR(smoking- kidney cancer):	RR(smoking- kidney cancer):										
			1.2	1.25	1.3	1.35	1.4	1.45	1.5	1.53	1.56	1.59	1.6
0.45	0.44		1.12	1.12	1.12	1.12	1.12	1.12	1.11	1.11	1.11	1.11	1.11
0.47	0.45		1.12	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11
0.49	0.46		1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.11	1.10	1.10
0.51	0.47		1.11	1.11	1.11	1.11	1.10	1.10	1.10	1.10	1.10	1.10	1.10
0.53	0.48		1.11	1.11	1.11	1.10	1.10	1.10	1.10	1.10	1.10	1.09	1.09
0.55	0.49		1.11	1.10	1.10	1.10	1.10	1.10	1.09	1.09	1.09	1.09	1.09
0.57	0.50		1.11	1.10	1.10	1.10	1.09	1.09	1.09	1.09	1.09	1.09	1.08
0.59	0.51		1.10	1.10	1.10	1.09	1.09	1.09	1.08	1.08	1.08	1.08	1.08
0.61	0.52		1.10	1.10	1.09	1.09	1.09	1.08	1.08	1.08	1.08	1.08	1.08
0.63	0.53		1.10	1.10	1.09	1.09	1.08	1.08	1.08	1.08	1.07	1.07	1.07
0.65	0.54		1.10	1.09	1.09	1.08	1.08	1.08	1.07	1.07	1.07	1.07	1.07

* Prevalence of smoking at Camp Lejeune
 # Prevalence of smoking at Camp Pendleton

Highlighting: reduction in the HR for kidney cancer by adjusting for a 4% difference in smoking prevalence between Camp Lejeune and Camp Pendleton. The HR of 1.12 would decrease between 1.10 and 1.11.

Note: To fully explain the kidney cancer HR of 1.12, the smoking prevalence difference between the two bases would have to be much greater than 11%.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 15. Alcohol use prevalence required to fully explain the hazard ratio of 0.74 in the analysis of the base location of civilian workers and chronic liver disease mortality as an underlying cause. The RRs for alcohol use and chronic liver disease mortality were assumed to be between 2.5 and 10.0.

Multidimensional HR CL-chronic liver disease mortality Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)*	p(alcohol use+ CL-)#	RR(alcohol use-chronic liver disease mortality):											
			2.5	3	3.5	4	5	6	6.5	7	8	9	10
0.33	0.48		0.86	0.88	0.90	0.91	0.94	0.96	0.96	0.97	0.98	0.99	1.00
0.33	0.49		0.86	0.89	0.91	0.92	0.95	0.97	0.98	0.98	1.00	1.01	1.02
0.33	0.50		0.87	0.90	0.92	0.94	0.96	0.98	0.99	1.00	1.01	1.02	1.03
0.33	0.51		0.88	0.91	0.93	0.95	0.98	1.00	1.01	1.01	1.03	1.04	1.05
0.33	0.52		0.89	0.92	0.94	0.96	0.99	1.01	1.02	1.03	1.04	1.06	1.07
0.33	0.53		0.89	0.92	0.95	0.97	1.00	1.03	1.04	1.04	1.06	1.07	1.08
0.33	0.54		0.90	0.93	0.96	0.98	1.01	1.04	1.05	1.06	1.08	1.09	1.10
0.33	0.55		0.91	0.94	0.97	0.99	1.03	1.05	1.07	1.07	1.09	1.11	1.12
0.33	0.56		0.92	0.95	0.98	1.00	1.04	1.07	1.08	1.09	1.11	1.12	1.13
0.33	0.57		0.92	0.96	0.99	1.01	1.05	1.08	1.09	1.10	1.12	1.14	1.15
0.33	0.58		0.93	0.97	1.00	1.03	1.07	1.10	1.11	1.12	1.14	1.15	1.17

* Prevalence of alcohol use at Camp Lejeune
 # Prevalence of alcohol use at Camp Pendleton

To fully explain the HR of 0.74 for chronic liver disease mortality and base location, the prevalence difference between CL and CP would range between 15% and 25% (highlighted).

Alcohol consumption and liver cirrhosis mortality RRs: 2.65 for 25 g/day, 6.83 for 50 g/day, and 16.38 for 100 g/day.
 Llamosas-Falcon L, Probst C, Buckler C, Jiang H et al. How does alcohol use impact morbidity and mortality of liver cirrhosis? A systematic review and dose-response meta-analysis. Hepatology International 08 September 2023 online ahead of print.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 16. Impact of adjusting for alcohol use prevalence difference of 15% between CL and CP on the HR of 1.19 for female breast cancer in the civilian workers analysis of base location. The RRs for alcohol use and female breast cancer were assumed to be between 1.1 and 1.6.

Multidimensional HR CL-female breast cancer Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)*	p(alcohol use+ CL-)#	RR(alcohol use-female breast cancer):	RR values for alcohol use prevalence difference of 15%										
			1.1	1.15	1.2	1.25	1.3	1.35	1.4	1.45	1.5	1.55	1.6
0.33	0.44		1.20	1.20	1.21	1.22	1.22	1.23	1.23	1.24	1.24	1.25	1.25
0.33	0.45		1.20	1.21	1.21	1.22	1.22	1.23	1.24	1.24	1.25	1.25	1.26
0.33	0.46		1.20	1.21	1.21	1.22	1.23	1.23	1.24	1.25	1.25	1.26	1.26
0.33	0.47		1.20	1.21	1.22	1.22	1.23	1.24	1.24	1.25	1.26	1.26	1.27
0.33	0.48		1.20	1.21	1.22	1.23	1.23	1.24	1.25	1.26	1.26	1.27	1.27
0.33	0.49		1.20	1.21	1.22	1.23	1.24	1.24	1.25	1.26	1.27	1.27	1.28
0.33	0.50		1.20	1.21	1.22	1.23	1.24	1.25	1.26	1.26	1.27	1.28	1.29
0.33	0.51		1.21	1.22	1.23	1.23	1.24	1.25	1.26	1.27	1.28	1.28	1.29
0.33	0.52		1.21	1.22	1.23	1.24	1.25	1.26	1.26	1.27	1.28	1.29	1.30
0.33	0.53		1.21	1.22	1.23	1.24	1.25	1.26	1.27	1.28	1.29	1.30	1.30
0.33	0.54		1.21	1.22	1.23	1.24	1.25	1.26	1.27	1.28	1.29	1.30	1.31

* Prevalence of alcohol use at Camp Lejeune
 # Prevalence of alcohol use at Camp Pendleton

The increase in the HR for female breast cancer by adjusting for a 15% difference in alcohol use prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.19 would increase to between 1.20 and 1.27.

RR for female breast cancer and moderate alcohol use (12.5g/day – 50g/day) = 1.23
 RR for female breast cancer and heavy alcohol use (>50g/day) = 1.61
 Ref. 34

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 17. Impact of adjusting for alcohol use prevalence difference of 15% between CL and CP on the HR of 1.19 for laryngeal cancer in the civilian workers analysis of base location. The RRs for alcohol use and laryngeal cancer are assumed to be between 1.1 and 3.0.

Multidimensional HR CL-laryngeal cancer Relationship Adjusted for alcohol use													
p(alcohol use+ CL+)*	p(alcohol use+ CL-)#	RR(alcohol use-laryngeal cancer):	1.1	1.3	1.5	1.7	1.9	2.1	2.3	2.5	2.7	2.9	3
			0.33	0.45	1.20	1.22	1.24	1.26	1.28	1.30	1.31	1.32	1.34
0.33	0.46	1.20	1.22	1.25	1.27	1.29	1.31	1.32	1.34	1.35	1.36	1.36	1.37
0.33	0.47	1.20	1.23	1.25	1.28	1.30	1.31	1.33	1.35	1.36	1.37	1.37	1.38
0.33	0.48	1.20	1.23	1.26	1.28	1.30	1.32	1.34	1.36	1.37	1.39	1.39	1.39
0.33	0.49	1.20	1.23	1.26	1.29	1.31	1.33	1.35	1.37	1.39	1.40	1.41	1.41
0.33	0.50	1.20	1.24	1.27	1.30	1.32	1.34	1.36	1.38	1.40	1.42	1.42	1.42
0.33	0.51	1.20	1.24	1.27	1.30	1.33	1.35	1.37	1.39	1.41	1.43	1.44	1.44
0.33	0.52	1.20	1.24	1.28	1.31	1.34	1.36	1.39	1.41	1.43	1.44	1.45	1.45
0.33	0.53	1.20	1.25	1.28	1.32	1.35	1.37	1.40	1.42	1.44	1.46	1.47	1.47
0.33	0.54	1.21	1.25	1.29	1.32	1.35	1.38	1.41	1.43	1.45	1.47	1.48	1.48
0.33	0.55	1.21	1.25	1.29	1.33	1.36	1.39	1.42	1.44	1.46	1.48	1.49	1.49

* Prevalence of alcohol use at Camp Lejeune
 # Prevalence of alcohol use at Camp Pendleton

The increase in the HR for laryngeal cancer by adjusting for a 15% difference in alcohol use prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.19 would increase to between 1.20 and 1.39.

RR for laryngeal cancer and moderate alcohol use (12.5g/day – 50g/day) = 1.44

RR for laryngeal cancer and heavy alcohol use (>50g/day) = 2.65

Ref. 34

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

Figure 18. Impact of adjusting for alcohol use prevalence difference of 15% between CL and CP on the HR of 1.67 for oral cancers in the civilian workers analysis of base location. The RRs for alcohol use and oral cancers were assumed to be between 1.25 and 5.25.

Multidimensional HR CL-oral cavity and pharynx Relationship Adjusted for alcohol													
p(alcohol+ CL+)*	p(alcohol+ CL-)#	RR(alcohol-oral cancers):	RR values for alcohol use prevalence difference of 15%										
			1.25	1.5	1.75	2	2.5	3	3.5	4	4.5	5	5.25
0.33	0.43		1.71	1.74	1.77	1.80	2.50	1.87	1.90	1.92	1.94	1.96	1.97
0.33	0.44		1.71	1.75	1.78	1.81	2.75	1.89	1.92	1.95	1.97	1.99	2.00
0.33	0.45		1.72	1.76	1.79	1.82	1.87	1.91	1.95	1.97	2.00	2.02	2.03
0.33	0.46		1.72	1.76	1.80	1.83	1.89	1.93	1.97	2.00	2.02	2.04	2.05
0.33	0.47		1.72	1.77	1.81	1.85	1.91	1.95	1.99	2.02	2.05	2.07	2.08
0.33	0.48		1.73	1.78	1.82	1.86	1.92	1.97	2.01	2.05	2.08	2.10	2.11
0.33	0.49		1.73	1.79	1.83	1.87	1.94	1.99	2.04	2.07	2.10	2.13	2.14
0.33	0.50		1.74	1.79	1.84	1.88	1.96	2.01	2.06	2.10	2.13	2.16	2.17
0.33	0.51		1.74	1.80	1.85	1.90	1.97	2.03	2.08	2.12	2.16	2.19	2.20
0.33	0.52		1.74	1.81	1.86	1.91	1.99	2.05	2.11	2.15	2.19	2.22	2.23
0.33	0.53		1.75	1.81	1.87	1.92	2.01	2.07	2.13	2.17	2.21	2.25	2.26

* Prevalence of alcohol use at Camp Lejeune
 # Prevalence of alcohol use at Camp Pendleton

The increase in the HR for oral cancers by adjusting for a 15% difference in alcohol use prevalence between Camp Lejeune and Camp Pendleton is highlighted. The HR of 1.67 would increase to between 1.73 and 2.11.

Abbreviations: HR – hazard ratio, RR – risk ratio, CL – Camp Lejeune, CP – Camp Pendleton

RR for oral cancer and moderate alcohol use (12.5g/day – 50g/day) = 1.83.

RR for oral cancer and heavy alcohol use (>50g/day) = 5.13. Ref. 34

Table S2-1a. Hazard ratios for cause of death related to smoking or alcohol consumption for the subgroup of Marines/Navy personnel comparing CL versus CP.

Outcome	Underlying cause				Contributing cause			
	Total cases	Camp Lejeune (# cases)	Camp Pendleton (# cases)	Adjusted HR (95% CI)	Total cases	Camp Lejeune (# cases)	Camp Pendleton (# cases)	Adjusted HR (95% CI)
alcoholism	544	242	302	0.90 (0.76, 1.07)	2,413	1,072	1,341	0.90 (0.83, 0.98)
alcoholic liver disease	901	381	520	0.86 (0.76, 0.99)	1,208	506	702	0.84 (0.75, 0.95)
chronic liver disease	1,389	614	775	0.93 (0.83, 1.03)	2,310	996	1,314	0.88 (0.81, 0.96)
COPD	632	312	320	1.08 (0.93, 1.27)	1,700	809	891	1.02 (0.93, 1.12)
cardiovascular disease	8,966	4,316	4,650	0.99 (0.95, 1.03)	14,848	7,107	7,741	0.98 (0.95, 1.01)

Abbreviations: CP - Camp Pendleton, CL – Camp Lejeune, HR – hazard ratio, CI – confidence interval, COPD – Chronic obstructive pulmonary disease

HRs adjusted for sex, race, rank and education level.

Table S2-1b. Hazard ratios for cause of death related to smoking or alcohol consumption for the civilian workers comparing CL versus CP.

Outcome	Underlying cause				Contributing cause			
	Total cases	Camp Lejeune (# cases)	Camp Pendleton (# cases)	Adjusted HR (95% CI)	Total cases	Camp Lejeune (# cases)	Camp Pendleton (# cases)	Adjusted HR (95% CI)
alcoholism	17	7	10	0.62 (0.23, 1.71)	81	33	48	0.66 (0.41, 1.05)
alcoholic liver disease	49	16	33	0.54 (0.29, 1.00)	61	21	40	0.58 (0.34, 1.01)
chronic liver disease	87	36	51	0.74 (0.48, 1.15)	150	59	91	0.66 (0.47, 0.92)
COPD	384	171	213	0.91 (0.74, 1.12)	871	418	453	1.05 (0.92, 1.20)
cardiovascular disease	2,377	1,105	1,272	0.91 (0.83, 0.99)	3,831	1,785	2,046	0.90 (0.84, 0.96)

Abbreviations: CP - Camp Pendleton, CL – Camp Lejeune, HR – hazard ratio, CI – confidence interval, COPD – Chronic obstructive pulmonary disease

HRs adjusted for sex, race, blue collar work (y/n) and education level.

Table S2-2a. Hazard ratios comparing the subgroup of Camp Lejeune and Camp Pendleton Marines/Navy personnel, adjusted for nondifferential exposure misclassification.

Sensitivity	Specificity	% false positive	Lung cancer	Laryngeal cancer	Esophageal cancer	AML
			1.16 [£]	1.21 [£]	1.27 [£]	1.38 [£]
1.00	0.91	10%	1.18	1.24	1.30	1.42
1.00	0.875	15%	1.19	1.25	1.32	1.44
1.00	0.84	20%	1.21	1.27	1.34	1.47
1.00	0.81	25%	1.22	1.28	1.36	1.50

AML: acute myeloid leukemia

£: Adjusted Hazard Ratio from Table 4

Table S2-2b. Hazard ratios comparing the Camp Lejeune and Camp Pendleton workers, adjusted for nondifferential exposure misclassification.

Sensitivity	Specificity	% false positive	Lung cancer	Laryngeal cancer	Oral cancers	Kidney cancer	Non-Hodgkin lymphoma	Female breast cancer
			1.15 [£]	1.18 [£]	1.67 [£]	1.12 [£]	1.19 [£]	1.19 [£]
1.00	0.91	10%	1.16	1.20	1.73	1.14	1.21	1.21
1.00	0.875	15%	1.16	1.20	1.74	1.14	1.22	1.22
1.00	0.84	20%	1.18	1.22	1.81	1.15	1.23	1.23
1.00	0.81	25%	1.19	1.23	1.85	1.16	1.24	1.24

£: Adjusted Hazard Ratio from Table 5